Who are Docetaxel+ carboplatin+ trastuzumab + patuzumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Docetaxel + Carboplatin + Trastuzumab + Pertuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-carboplatin-trastuzumab-patuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Docetaxel+ carboplatin+ trastuzumab + patuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel+ carboplatin+ trastuzumab + patuzumab (Docetaxel+ carboplatin+ trastuzumab + patuzumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with HER2-targeted monoclonal antibodies. Area: Oncology.

phase 3 Combination chemotherapy with HER2-targeted monoclonal antibodies HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel+ carboplatin+ trastuzumab + patuzumab (Docetaxel+ carboplatin+ trastuzumab + patuzumab) — Henan Cancer Hospital. This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit cancer cell division and HER2-mediated growth signaling.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docetaxel+ carboplatin+ trastuzumab + patuzumab TARGET	Docetaxel+ carboplatin+ trastuzumab + patuzumab	Henan Cancer Hospital	phase 3	Combination chemotherapy with HER2-targeted monoclonal antibodies	HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin)
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab	Docetaxel + Carboplatin + Trastuzumab + Pertuzumab	Henan Cancer Hospital	phase 3	Combination chemotherapy with HER2-targeted monoclonal antibodies	HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with HER2-targeted monoclonal antibodies class)

Henan Cancer Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel+ carboplatin+ trastuzumab + patuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-carboplatin-trastuzumab-patuzumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab